CTLA4 and neoplasm: ICIs release the brake of the immune system during priming of naive T-cells [anti-CTLA-4, but more recently also shown for anti-PD-(L)1 (3, 4)] and during reactivation of memory anti-cancer T-cell responses (anti-PD-(L)1), rather than inducing direct tumor cell death as conventional therapies.